American Society of Clinical Oncology annual meeting, a study recently released report shows that cholesterol-lowering drugs “Sida Ding” at least 50% reduction in risk of breast cancer, although its safety and efficacy remain to be further verified.
Louisiana University Health Sciences Research Center, researchers obtained from 1998 to 2004 the U.S. Department of Veterans Affairs is responsible for care of the relevant records of ex-female, compared 556 women suffering from breast cancer and 39865 healthy women taking ” Sida Ding “situation. The results showed that, in the six years of the study, those who received “Sida Ding” women’s risk of breast cancer than those without taking “Sida Ding” lower 51% of women.
The researchers found through laboratory studies, called HMG-COA of the enzyme may play a role in cancer cell proliferation in, “Sida Ding” can inhibit the activity of this enzyme, thereby preventing cells from becoming cancerous process, to prevent tumor formation. The researchers said it is only “Sida Ding,” a role, it may also help to take, “Sida Ding” to reduce cancer risk for women.
The researchers also pointed out that, due to “Sida Ding” reduce the carcinogenic risk of not fully understand the mechanism of action, and now people are taking on the proposed “Sida Ding” to reduce the risk of breast cancer is premature. Medical need for further research to prove, “Sida Ding,” the anti-cancer efficacy and safety. But for patients with high cholesterol, the “Sida Ding” is undoubtedly a better choice.
Cholesterol-lowering drugs are often used to combat cardiovascular disease, and “Sida Ding” is the most important cholesterol-lowering drugs, a class, which by blocking the synthesis of cholesterol in the human body to achieve the cholesterol-lowering purposes.
15, according to Agence France-Presse reported that the Annual General Meeting American Society of Clinical Oncology published a study reported that Statins (Statins) and other cholesterol-lowering drugs used in breast cancer risk can be reduced by 50% or more.
According to a recent study of several independent reports indicate that statins can also make the history of the risk of lung cancer, as well as the risk of prostate cancer decreased by 48% and 54% respectively. Lipitor and simvastatin and other common cholesterol-lowering statin drugs containing history.
Louisiana University Health Sciences Center Associate Professor of Medicine Vikas Khurana of the study’s authors. His May 14 at the American Society of Clinical Oncology annual meeting, said: “I think for those women who are at high risk of breast cancer, history of statin has a very important preventive role.” However, Khurana stressed that, now tell people to take these drugs to reduce the risk of breast cancer is premature.
The researchers compared 556 women suffering from breast cancer and 39865 have never won the history of this disease in women with statins results.
British “The Times” May 14 reported that tests showed that with early HER-2 breast cancer in women after surgery, in addition to the standard drug, plus taking the drug Herceptin (Herceptin), the disease recurrence rate of the lower 46 %. About 20% to 30% of women can benefit from this treatment because their tumors sensitive to the HER-2 protein. Experts believe that this discovery may be the treatment of breast cancer for many years a major leap forward. The initial findings indicate that early use of Herceptin, a year in the UK could save more than 2,800 breast cancer patients with HER-2 lives.
The results are the U.S. Society of Clinical Oncology meeting in Orlando, Florida announced. A total of 5000 patients including 500 from the United Kingdom —- —- accepted clinical trials.
London’s Royal Marsden Hospital, Professor Ian Smith, director of breast, said: “This exciting test results to become a milestone in breast cancer treatment. For people with HER-2 type of breast cancer patients, this is a very important progress. We now need to quickly develop plans to come to clinic to measure all of the HER-2 breast cancer patients, so as to determine which patients can benefit from this therapy. “At present, the United Kingdom only 35% of cancer centers in diagnosis of breast cancer to test HER-2 status.
